riluzole has been researched along with Nerve Degeneration in 15 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Infusion of the K(+) channel blocker 4-aminopyridine in the hippocampus induces the release of glutamate, as well as seizures and neurodegeneration." | 7.70 | Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels. ( Peña, F; Tapia, R, 2000) |
| "Riluzole is a neuroprotective drug used in the treatment of motor neurone disease." | 5.38 | Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012) |
| "Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum." | 5.33 | Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005) |
| "Infusion of the K(+) channel blocker 4-aminopyridine in the hippocampus induces the release of glutamate, as well as seizures and neurodegeneration." | 3.70 | Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels. ( Peña, F; Tapia, R, 2000) |
| "Riluzole is a neuroprotective drug used in the treatment of motor neurone disease." | 1.38 | Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012) |
| "Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum." | 1.33 | Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005) |
| "Neuronal death associated with cerebral ischemia and hypoglycemia is related to increased release of excitatory amino acids (EAA) and energy failure." | 1.33 | The anion channel blocker, 4,4'-dinitrostilbene-2,2'-disulfonic acid prevents neuronal death and excitatory amino acid release during glycolysis inhibition in the hippocampus in vivo. ( Camacho, A; Massieu, L; Montiel, T, 2006) |
| "Cotreatment with riluzole (4 mg/kg i." | 1.30 | Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. ( Brouillet, E; Guyot, MC; Hantraye, P; Mary, V; Palfi, S; Peschanski, M; Riche, D; Stutzmann, JM; Wahl, F, 1997) |
| "Riluzole treatment beyond 1 h (e." | 1.30 | Tirilazad widens the therapeutic window for riluzole-induced attenuation of progressive cortical degeneration in an infant rat model of the shaken baby syndrome. ( Hall, ED; Smith, SL, 1998) |
| "Riluzole treatment almost completely prevented the neuronal degeneration in these brain areas." | 1.30 | Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder. ( Kanthasamy, AG; Nguyen, B; Truong, DD; Yun, RJ, 1999) |
| "Riluzole was injected or topically applied to the eye before or after ischemia and twice daily during the reperfusion period." | 1.30 | Riluzole improves functional recovery after ischemia in the rat retina. ( Ettaiche, M; Fillacier, K; Heurteaux, C; Lazdunski, M; Widmann, C, 1999) |
| " Moreover, human monocytoid cell lines infected by HIV release endogenous toxic factors with comparable cellular actions." | 1.29 | Prevention of HIV coat protein (gp120) toxicity in cortical cell cultures by riluzole. ( Bousseau, A; Couratier, P; Esclaire, F; Hugon, J; Sindou, P; Yardin, C, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunet, N | 1 |
| Tarabal, O | 1 |
| Esquerda, JE | 1 |
| Calderó, J | 1 |
| Sanacora, G | 1 |
| Carbone, M | 1 |
| Duty, S | 1 |
| Rattray, M | 1 |
| Hersch, SM | 1 |
| Rival, T | 1 |
| Soustelle, L | 1 |
| Strambi, C | 1 |
| Besson, MT | 1 |
| Iché, M | 1 |
| Birman, S | 1 |
| Scherfler, C | 1 |
| Sather, T | 1 |
| Diguet, E | 1 |
| Stefanova, N | 1 |
| Puschban, Z | 1 |
| Tison, F | 1 |
| Poewe, W | 1 |
| Wenning, GK | 1 |
| Camacho, A | 1 |
| Montiel, T | 1 |
| Massieu, L | 1 |
| Amendola, J | 1 |
| Gueritaud, JP | 1 |
| Lamotte d'Incamps, B | 1 |
| Bories, C | 1 |
| Liabeuf, S | 1 |
| Allene, C | 1 |
| Pambo-Pambo, A | 1 |
| Durand, J | 1 |
| Sindou, P | 1 |
| Couratier, P | 1 |
| Esclaire, F | 1 |
| Yardin, C | 1 |
| Bousseau, A | 1 |
| Hugon, J | 1 |
| Dessi, F | 1 |
| Ben-Ari, Y | 1 |
| Charriaut-Marlangue, C | 1 |
| Palfi, S | 1 |
| Riche, D | 1 |
| Brouillet, E | 1 |
| Guyot, MC | 1 |
| Mary, V | 1 |
| Wahl, F | 1 |
| Peschanski, M | 1 |
| Stutzmann, JM | 1 |
| Hantraye, P | 1 |
| Smith, SL | 1 |
| Hall, ED | 1 |
| Kanthasamy, AG | 1 |
| Yun, RJ | 1 |
| Nguyen, B | 1 |
| Truong, DD | 1 |
| Ettaiche, M | 1 |
| Fillacier, K | 1 |
| Widmann, C | 1 |
| Heurteaux, C | 1 |
| Lazdunski, M | 1 |
| Peña, F | 1 |
| Tapia, R | 1 |
2 reviews available for riluzole and Nerve Degeneration
| Article | Year |
|---|---|
Do glutamatergic agents represent a new class of antidepressant drugs? Part 1.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Drug Design; Hum | 2009 |
Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation.
Topics: Amantadine; Anti-Dyskinesia Agents; Antiparkinson Agents; Eicosapentaenoic Acid; Fatty Acids, Unsatu | 2003 |
13 other studies available for riluzole and Nerve Degeneration
| Article | Year |
|---|---|
Excitotoxic motoneuron degeneration induced by glutamate receptor agonists and mitochondrial toxins in organotypic cultures of chick embryo spinal cord.
Topics: Animals; Calcium Signaling; Chick Embryo; Disease Models, Animal; Dose-Response Relationship, Drug; | 2009 |
Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
Topics: Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Excitatory Amino | 2012 |
Decreasing glutamate buffering capacity triggers oxidative stress and neuropil degeneration in the Drosophila brain.
Topics: Animals; Brain; DNA Primers; Drosophila; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Tr | 2004 |
Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy).
Topics: Animals; Biomarkers; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine and cAMP-Regulat | 2005 |
The anion channel blocker, 4,4'-dinitrostilbene-2,2'-disulfonic acid prevents neuronal death and excitatory amino acid release during glycolysis inhibition in the hippocampus in vivo.
Topics: Animals; Aspartic Acid; Brain Ischemia; Cell Death; Energy Metabolism; Excitatory Amino Acids; Exocy | 2006 |
Postnatal electrical and morphological abnormalities in lumbar motoneurons from transgenic mouse models of amyotrophic lateral sclerosis.
Topics: Action Potentials; Amyotrophic Lateral Sclerosis; Animals; Animals, Newborn; Biotin; Cell Differenti | 2007 |
Prevention of HIV coat protein (gp120) toxicity in cortical cell cultures by riluzole.
Topics: Animals; Cells, Cultured; Cerebral Cortex; Excitatory Amino Acid Antagonists; HIV Envelope Protein g | 1994 |
Riluzole prevents anoxic injury in cultured cerebellar granule neurons.
Topics: Animals; Cells, Cultured; Cerebellum; Hypoxia, Brain; Nerve Degeneration; Neurons; Rats; Riluzole; S | 1993 |
Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Topics: Acetylcholinesterase; Animals; Antiparkinson Agents; Apomorphine; Caudate Nucleus; Corpus Striatum; | 1997 |
Tirilazad widens the therapeutic window for riluzole-induced attenuation of progressive cortical degeneration in an infant rat model of the shaken baby syndrome.
Topics: Age Factors; Animals; Battered Child Syndrome; Body Temperature; Disease Models, Animal; Dose-Respon | 1998 |
Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Heart Arrest; Histocytochemistry; Male; Movement D | 1999 |
Riluzole improves functional recovery after ischemia in the rat retina.
Topics: Administration, Topical; Animals; Apoptosis; Electroretinography; Glial Fibrillary Acidic Protein; I | 1999 |
Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels.
Topics: 4-Aminopyridine; Animals; Epilepsy; Excitatory Amino Acid Antagonists; GABA Agonists; GABA Antagonis | 2000 |